GSK stock: buy or sell?

GSK stock price: $42.53 0.14% At close on October 18th, 2019

Updated on:
October 18th, 2019

5

GlaxoSmithKline stayed constant a tight 0.14% and closed at $42.53. Oct 18th was the fourth climbing session in a row, marking 0.85%.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide.

Should I buy GSK stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with GlaxoSmithKline stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean GSK will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is GlaxoSmithKline stock a buy?

Banks and financial institutions publish stock ratings everyday. At Stocks2.com, we collected 15 ratings published for GSK stock in the last month.

Is GSK a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-30Shore Capitaln/aHold
2019-9-30Jefferies Financial Groupn/aBuy
2019-9-30Deutsche Bankn/aHold
2019-9-3Societe GeneraleSellBuy
2019-9-3Citigroupn/aNeutral
2019-9-27UBS Groupn/aNeutral
2019-9-27JPMorgan Chase & Co.n/aNeutral
2019-9-27Goldman Sachs Groupn/aBuy
2019-9-26Barclaysn/aNeutral
2019-9-20JPMorgan Chase & Co.n/aNeutral
2019-9-2Deutsche Bankn/aHold
2019-9-13Barclaysn/aEqual weight
2019-9-13Bank of American/aNeutral
2019-9-10HSBCn/aBuy
2019-8-29Jefferies Financial Groupn/aBuy

GSK stock analysis

Daily outlook

GlaxoSmithKline stayed stable a tight 0.14% and closed at $42.53.

Shares of GlaxoSmithKline closed on Oct 18th at $42.53 and stayed stable a tight 0.14%. Since price and SMA200d lines crossed up on June, GSK climbed $4.30 (11.25%). Since last July when SMA50d and SMA100d crossed up, GSK price gained $1.58 per share (3.86%). On Sep/30, GSK hit a new all time high, pushing higher than on Sep 26th tops. Check different trading setups that use ATHs as triggers.

GSK stock chart (daily)

Weekly outlook

GlaxoSmithKline shares grew 0.83% this week, ending at $42.53.

In a weekly time frame, GlaxoSmithKline stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, GSK might consolidate in a flat-base, waiting to break out over or down under . Not so far away is the last all-time high GlaxoSmithKline marked late September. Early June GSK price bounced up over the SMA of 40 weeks that acted as support stopping new slides. By mid March, SMA20w and SMA40w crossed up triggering a rise of 7.18%.

GSK stock chart (weekly)

GSK stock price history

GSK IPO was on March 28th, 1980 at $0.00 per share1. Since then, GSK stock grew a inf%, with a yearly average of inf%. If you had invested $1,000 in GSK stock in 1980, it would worth $inf today.

1: Adjusted price after possible price splits or reverse-splits.

GSK stock historical price chart

GSK stock reached all-time highs on Sep 30th with a price of $43.22.

GSK stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not found any price target for GlaxoSmithKline stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, GlaxoSmithKline reported its latest financial data, posting a remarkable gain for the Earnings per Share (EPS) ratio. Experts expected $0.70 per share, but GlaxoSmithKline posted $0.79.
GSK earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q2-n/a0.26n/a
2017-Q3-n/a0.31n/a
2017-Q4-n/a0.47n/a
2018-Q12018-04-250.70.68-2.9%
2018-Q22018-07-250.710.778.5%
2018-Q32018-10-310.860.83-3.5%
2018-Q42019-02-060.70.7912.9%
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a
2019-Q3-n/an/an/a

Annual financial results

In 2018, GlaxoSmithKline annual revenues inched a slightly good 2.10% to $30,821.00 million dollars from $30,186.00 marked in 2017. In line, its profit margin (compared to sales) rose to 11.75%, that is $3,623.00 million.

GSK annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$26,510 M-$5,440 M20.5%-
2014$35,840 M35.19%$4,293 M12.0%-21.08%
2015$23,923 M-33.25%$8,422 M35.2%96.16%
2016$27,889 M16.58%$912 M3.3%-89.17%
2017$30,186 M8.24%$1,532 M5.1%67.98%
2018$30,821 M2.10%$3,623 M11.8%136.49%

Quarterly financial results

GlaxoSmithKline posted $8,197.00 million in revenues for 2018-Q4, a 1.30% up compared to previous quarter. Reported quarter income marked $1,215.00 M with a profit margin of 14.82%. Profit margin depreciated a -2.70% compared to previous quarter when profit margin was 17.52%. When comparing sales to same quarter last year, GlaxoSmithKline sales marked a dreadful slide and plunged a -20.59%. Looking back to recent quarterly results, GlaxoSmithKline posted 3 positive quarters in a row.
GSK quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q2$7,320 M-$-180 M-2.5%-
2017-Q3$10,507 M43.54%$1,624 M15.5%-1,002.02%
2017-Q4$10,323 M-1.75%$-738 M-7.1%-145.44%
2018-Q1$7,222 M-30.04%$549 M7.6%-174.41%
2018-Q2$7,310 M1.22%$441 M6.0%-19.67%
2018-Q3$8,092 M10.70%$1,418 M17.5%221.54%
2018-Q4$8,197 M1.30%$1,215 M14.8%-14.32%
2019-Q1$7,661 M-6.54%$830 M10.8%-31.69%

GlaxoSmithKline ownership

When you are planning to invest in a company, it's worth to overview its ownership structure.

GlaxoSmithKline shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.01% of all shares.

In case of GlaxoSmithKline stock, 11.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for GSK stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to GlaxoSmithKline:

GSKAZNDVAXINVAMRK
Market cap$105.9 B$114.9 B$341.4 M$1.1 B$216.8 B
Total shares2,490.0 M2,620.0 M83.7 M101.3 M2,560.0 M
Float shares2,450.0 M2,610.0 M58.5 M53.5 M2,560.0 M
  - Institutional holdings (%)11.0%19.4%85.1%81.3%78.3%
  - Insider holdings (%)0.0%0.0%1.2%32.5%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

GSK summary

Friday, October 18th, 2019
Open$42.52
Close$42.53
Day range$42.37 - $42.64
Previous close$42.47
Session gain0.14%
Average true range$0.52
50d mov avg$41.47
100d mov avg$40.77
200d mov avg$39.92
Daily pattern
Weekly pattern lt06a

GlaxoSmithKline performance

To better understand GlaxoSmithKline performance you must compare its gains with other related stocks in same sector or industry. For GlaxoSmithKline, the comparison is made against Astrazeneca, Dynavax Technologies, Innoviva, Merck, Novartis, Pfizer, and Teva Pharmaceutical Industries.
Stock3m6m12m
GSKGlaxoSmithKline5.04%9.28%9.42%
AZNAstrazeneca10.48%14.24%15.63%
DVAXDynavax Technolog...11.48%-36.35%-62.53%
INVAInnoviva-19.42%-17.33%-30.93%
MRKMerck4.74%17.25%20.25%
NVSNovartis-7.14%13.70%14.80%
PFEPfizer-13.95%-5.72%-15.19%
SNY10.06%16.41%7.92%
TEVATeva Pharmaceutic...-5.18%-47.77%-65.00%

GlaxoSmithKline competitors

One check before trading any stock is to have a look a list of its competitors, in this case for GlaxoSmithKline. We chose 8 companies as GlaxoSmithKline competitors as they are in the same industry or have similar market objectives.

Latest GSK stock news